Jan 30, 2025 | by Austin Chelko, Commentary
My recent post on rebates sparked considerable interest, so I’m doubling down with a parallel topic that’s equally frustrating: broker overrides. Many of you know these are incentive commissions paid to brokers for bringing in new customers and renewing profitable arrangements—and they’re a pervasive problem in our industry.
In fact, the issues are so similarly egregious, I can pretty much use the same basic narrative from my rebates article for outlining my grievances. (more…)
Dec 20, 2024 | by Austin Chelko, Commentary, Value-Based Drug Management
We recently heard of a broker calling on employers with the promise of negotiating higher rebates, and only charging a modest “shared savings” price based on guaranteed increased rebates.
The unfortunate reality is that most buyers and brokers/consultants continue supporting the false narrative of larger rebates equating to a better deal. With rebates growing exponentially (especially in certain classes of drugs), the lure of what seems like a windfall of money is proving increasingly tough to resist for plan sponsors and their advisors. (more…)
Mar 27, 2024 | by Austin Chelko, Commentary, Value-Based Drug Management
The tide is turning in the PBM world! I’m here for it. In just the last few months here’s a snapshot of what’s transpired: (more…)
